Cite
A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia
MLA
Dieter Hoelzer, et al. “A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-RHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia.” Blood, vol. 94, Dec. 1999, pp. 3694–701. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....54c834dbd5e7392efa2454e14bf62b12&authtype=sso&custid=ns315887.
APA
Dieter Hoelzer, Caroline O’Brien-Ewen, Hervé Dombret, Klaus Lechner, Gerhard Heil, Eric Archimbaud, Miguel A. Sanz, Alan Barge, John A. Liu Yin, Oliver G. Ottmann, J Matcham, Wolfram Brugger, & Pierre Fenaux. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood, 94, 3694–3701.
Chicago
Dieter Hoelzer, Caroline O’Brien-Ewen, Hervé Dombret, Klaus Lechner, Gerhard Heil, Eric Archimbaud, Miguel A. Sanz, et al. 1999. “A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-RHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia.” Blood 94 (December): 3694–3701. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....54c834dbd5e7392efa2454e14bf62b12&authtype=sso&custid=ns315887.